Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1997-7-22
|
| pubmed:abstractText |
The chemotherapy side-effects are insufficiently documented while they strongly condition patients' quality of life. The aim of the study was to assess by means of a self-administered questionnaire the somatic symptoms experienced by breast cancer patients during their NCF (mitoxantrone + cyclophosphamide + 5-fluorouracil) chemotherapy and to demonstrate the interest of this self-report by comparing the frequency of side-effects assessed by the patients to that noted by the physicians in medical records. The study was carried out among 44 patients receiving their chemotherapy + radiotherapy at the Paoli-Calmettes Institute (marseille) between July 1994 and May 1995. The questionnaire comprized of 17 symptoms evaluated in terms of frequency, duration/severity and distress. The most frequent symptoms are: hair loss and nausea (75%), hot flush (57%), lack of appetite and headache (46%) associated with distress in 67 to 100% of cases. Their frequency was underestimated by the physicians in medical records. This study showed a large discordance patient-physician in the assessment of chemotherapy side-effects. The type of tool presented in this study could complement the usual scales of toxicity that do not provide an estimation of true patients' experience.
|
| pubmed:language |
fre
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0007-4551
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
84
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
240-6
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:9207868-Adult,
pubmed-meshheading:9207868-Aged,
pubmed-meshheading:9207868-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9207868-Breast Neoplasms,
pubmed-meshheading:9207868-Combined Modality Therapy,
pubmed-meshheading:9207868-Cyclophosphamide,
pubmed-meshheading:9207868-Data Interpretation, Statistical,
pubmed-meshheading:9207868-Female,
pubmed-meshheading:9207868-Fluorouracil,
pubmed-meshheading:9207868-Humans,
pubmed-meshheading:9207868-Middle Aged,
pubmed-meshheading:9207868-Mitoxantrone,
pubmed-meshheading:9207868-Neoplasm Staging,
pubmed-meshheading:9207868-Physician-Patient Relations,
pubmed-meshheading:9207868-Quality of Life,
pubmed-meshheading:9207868-Questionnaires,
pubmed-meshheading:9207868-Self-Assessment,
pubmed-meshheading:9207868-Treatment Outcome
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
[Adjuvant chemotherapy with mitoxantrone, cyclophosphamide and 5-fluorouracil in breast neoplasms: therapeutic life].
|
| pubmed:affiliation |
Institut Paoli-Calmettes, Marseille, France.
|
| pubmed:publicationType |
Journal Article,
English Abstract,
Research Support, Non-U.S. Gov't
|